Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Weight, GLP-1 & Metabolic Therapy

CoverageWeight, GLP-1 & Metabolic Therapy

How does tirzepatide compare with semaglutide for weight loss?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·11 studies analyzed·2 core studies·Applies to: men with preexisting or high cardiovascular risk

Bottom line

Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. Head-to-head cardiovascular outcome comparisons remain incomplete across approved indications.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Mounjaro vs Ozempic weight▼

SURMOUNT-5 and related head-to-head data show greater mean weight loss with tirzepatide (Mounjaro/Zepbound) than semaglutide 2.4 mg (Wegovy) at studied doses over 72 weeks.

Why would a doctor prescribe semaglutide instead of tirzepatide?▼

Semaglutide may be chosen for longer cardiovascular outcome data in type 2 diabetes, formulary coverage, prior tolerance, oral formulation preference, or specific labeled indications.

What makes you less sick, semaglutide or tirzepatide?▼

Gastrointestinal side effects are common with both agents and vary by patient. Titration speed and dose affect tolerability more than a universal winner across individuals.

Tirzepatide vs semaglutide which is safer?▼

Both carry class warnings including thyroid medullary carcinoma risk in rodents. Head-to-head safety profiles are broadly similar for GI events; long-term comparative cardiovascular safety is still emerging.

Tirzepatide semaglutide comparison▼

Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.

Do semaglutide and tirzepatide differ in how much weight patients lose?▼

Head-to-head trials suggest tirzepatide produces greater average weight loss than semaglutide at studied doses, with broadly similar gastrointestinal side-effect profiles. Long-term cardiovascular outcome comparisons are ongoing.

At a glance

DimensionTirzepatide (Mounjaro / Zepbound)Semaglutide (Ozempic / Wegovy)
Drug classGIP + GLP-1 dual agonistGLP-1 agonist
FDA approvalsType 2 diabetes (Mounjaro); obesity (Zepbound)Type 2 diabetes (Ozempic); obesity (Wegovy); CV risk reduction (Wegovy)
Weight loss (RCT range)~15–22% at max dose (SURMOUNT series)~12–15% at 2.4 mg (STEP series)
Head-to-head evidenceGreater average weight loss in SURMOUNT-5Lower average weight loss in SURMOUNT-5
Cardiovascular outcome dataSURPASS-CVOT ongoing; CV data emergingSELECT (2023) showed MACE reduction in high-risk non-diabetics
Dosing frequencyOnce weekly subcutaneous injectionOnce weekly subcutaneous injection (oral semaglutide available for diabetes)

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 11 relevant studies.

Overall finding

9 studies address weight / body composition, with weighted findings showing benefit. 2 studies address hba1c / glycemic control, with weighted findings showing benefit. 1 study addresses blood pressure, with weighted findings showing benefit. 1 study addresses ldl-c, with weighted findings showing benefit. 5 randomized or systematic-review reports and 6 observational studies address treatment. Choose between tirzepatide and semaglutide based on weight-loss goals, tolerability, access, and comorbidity rather than assuming equivalence.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Favors treatment

Weight / body composition

moderate · 9 studies

9 studies address weight / body composition, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987PMID 33567185PMID 27295427PMID 42600634PMID 39941615PMID 42060800PMID 42588312PMID 42145153PMID 41909366
Favors treatment

HbA1c / glycemic control

moderate · 2 studies

2 studies address hba1c / glycemic control, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987PMID 42060800
Favors treatment

Blood pressure

moderate · 1 study

1 study addresses blood pressure, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987
Favors treatment

LDL-C

moderate · 1 study

1 study addresses ldl-c, with weighted findings showing benefit. This is an objectively measured outcome. This is a surrogate endpoint and does not by itself prove a hard clinical outcome.

Objectively measured · Surrogate endpoint

Studies

PMID 40537987
Unclear

Major adverse cardiovascular events

moderate · 1 study

1 study addresses major adverse cardiovascular events, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 37952131
Unclear

Mortality

moderate · 1 study

1 study addresses mortality, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 27633186

Magnitude / clinical importance

Validated effect estimates in the analyzed set include hazard ratio.; or 1.0; odds ratio=1.34. Statistical significance is not the same as clinical importance.

Interpret magnitude in absolute terms for the patient in front of you, not from relative estimates alone.

Agreement across studies

Findings are mixed after weighting by design, quality, and directness.

Supports main conclusion: 1 · Neutral / mixed: 8 · Credible conflicting: 2

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
  • In the time-to-event analysis, the rate of the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among patients with type 2 diabetes mellitus wa…
  • Obesity and type 2 diabetes mellitus (T2DM) are widespread health concerns that often coexist, contributing to increased cardiometabolic risks and premature death.

Risks & harms

5 studies report safety-relevant findings. Design mix: Randomized controlled trial, Study design not clearly classified, Narrative review, Expert opinion / editorial. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

The evidence set is heterogeneous. The most recurrent population is men with preexisting or high cardiovascular risk, but several distinct groups were studied.

What remains uncertain

  • Head-to-head cardiovascular outcome comparisons remain incomplete across approved indications.
  • Head-to-head cardiovascular outcome comparisons remain incomplete across approved indications.

Clinical takeaway

Choose between tirzepatide and semaglutide based on weight-loss goals, tolerability, access, and comorbidity rather than assuming equivalence. Head-to-head data favor greater average weight loss with tirzepatide at studied doses; cardiovascular comparisons remain ongoing.

Favors treatment

Weight / body composition?

Benefit

moderate[40537987 · 33567185 · 27295427 · 42600634 · 39941615 · 42060800 · 42588312 · 42145153 · 41909366]

Favors treatment

HbA1c / glycemic control?

Benefit

moderate[40537987 · 42060800]

Favors treatment

Blood pressure?

Benefit

moderate[40537987]

Favors treatment

LDL-C?

Benefit

moderate[40537987]

Unclear

Major adverse cardiovascular events?

Unclear findings

moderate[37952131]

Unclear

Mortality?

Unclear findings

moderate[27633186]

Unclear

Bone mineral density?

Unclear findings

limited[42588312]

5 randomized or systematic-review reports and 6 observational studies address treatment. Weighted treatment findings show benefit.

5 RCT / systematic review · 6 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

9 supporting studies add context beyond the core evidence base.

Regimen & duration

Observational and supporting studies provide context and do not outrank higher-appropriateness designs.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

11 analyzed studies

Strongest evidence

Diabetes, obesity & metabolism2025

Landmark studyPMID 40537987

Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.

AIMS: This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2. MATERIALS AND METHODS: Participants had body mass index (BMI) ≥ 27 kg/m 2 , with ≥1 unsuccessful prior dietary weight reduction effort and glycated haemoglobin (HbA1c) 7%-10% on stable therapy.

RCT
Evidence
Relevance
The New England journal of medicine2021

Landmark studyPMID 33567185

Once-Weekly Semaglutide in Adults with Overweight or Obesity.

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).

RCT
Evidence
Relevance

Supporting literature

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

+6 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Weight, GLP-1 & Metabolic Therapy.

Does GLP-1 treatment cause meaningful muscle loss?

GLP-1 therapies reduce weight through fat and lean mass loss; lean loss is partly proportional to total weight lost. Resistance training and adequate protein may mitigate but not eliminate lean mass decline.

11 linked studies

Do GLP-1 receptor agonists reduce major cardiovascular events?

GLP-1 receptor agonists with cardiovascular outcome trials (including liraglutide and semaglutide in selected populations) reduce major adverse cardiovascular events beyond glucose lowering in high-risk patients with type 2 diabetes or obesity.

14 linked studies

Do patients regain weight after stopping GLP-1 therapy?

Clinical trials and observational follow-up show substantial weight regain after GLP-1 discontinuation, suggesting chronic therapy may be needed to maintain benefit unless durable lifestyle changes are established.

11 linked studies

Do GLP-1 agonists increase pancreatitis risk?

Early signals raised pancreatitis concern, but large trials and post-marketing data have not confirmed a strong causal increase at population level. Caution remains reasonable in patients with prior pancreatitis.

11 linked studies

Go deeper on Weight, GLP-1 & Metabolic Therapy

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Weight, GLP-1 & Metabolic TherapyView pricing